What is the recommended dosing, administration, and monitoring for asenapine in adults with schizophrenia (including dose adjustments for patients over 65 years or with hepatic impairment) and in bipolar I disorder?

Asenapine Dosing and Administration

For schizophrenia in adults, start asenapine at 5 mg sublingual twice daily, which can be increased to 10 mg twice daily after one week if tolerated; for patients over 65 years, no dose adjustment is required but use caution with slower titration, and for hepatic impairment, reduce doses in patients with moderate to severe dysfunction. 1

Schizophrenia Dosing

Standard Adult Dosing

• Initial dose: 5 mg sublingual twice daily
• Target dose: 5-10 mg twice daily
• Maximum dose: 10 mg twice daily
• Dose increases should occur after at least one week at the initial dose 1, 2, 3

The 5 mg twice daily dose demonstrated superiority over placebo in acute schizophrenia trials, with significant improvements in Positive and Negative Syndrome Scale (PANSS) scores 3. Real-world evidence suggests doses >10 mg/day may be more effective than ≤10 mg/day in maintenance treatment, though this requires individual assessment 4.

Elderly Patients (≥65 years)

• No formal dose adjustment required per FDA labeling 1
• However, start with slower titration: 2 mg twice daily for 2 days, then 5 mg twice daily for 2 days, before advancing to 10 mg twice daily 5
• Pharmacokinetic studies show 12-30% increases in drug exposure in elderly patients, but this was generally well tolerated 5
• Monitor closely for orthostatic hypotension, sedation, and extrapyramidal symptoms

Hepatic Impairment

• Moderate to severe hepatic impairment: Reduce dose 6
• The FDA label recommends dose reduction in patients with hepatic impairment, though specific dosing is not detailed 1
• Use caution and start at lower end of dosing range

Bipolar I Disorder Dosing

Acute Manic or Mixed Episodes

• Initial and target dose: 10 mg sublingual twice daily (starting on day 1)
• Flexible dosing: 5-10 mg twice daily after day 1 7
• Efficacy demonstrated as early as day 2 of treatment 7

Critical Administration Requirements

Sublingual Formulation

Asenapine has <2% bioavailability if swallowed; sublingual administration is mandatory 1, 2, 8, 9:

• Place tablet under tongue and allow to dissolve completely
• Do not eat or drink for 10 minutes after administration (minimum 2 minutes, though 10 minutes recommended) 1, 8, 9
• Do not swallow for at least 10 minutes
• Twice-daily dosing required due to pharmacokinetics

Transdermal Formulation (SECUADO)

Available for schizophrenia only 1:

• 3.8 mg/24 hours or 7.6 mg/24 hours patch
• Apply once daily to clean, dry skin
• Rotate application sites
• Common application site reactions (erythema, pruritis) occur in 15% at 3.8 mg and 14% at 7.6 mg 1

Monitoring Requirements

Baseline (Before Starting Treatment)

• BMI and waist circumference
• Blood pressure
• Fasting glucose or HbA1c
• Lipid panel
• Prolactin level
• Liver function tests (ALT, AST)
• Complete blood count
• Electrocardiogram
• Extrapyramidal symptom assessment 10, 11

During Titration

• Weeks 1-6: Weekly BMI, waist circumference, and blood pressure 10
• Week 4: Repeat fasting glucose 10
• Monitor for extrapyramidal symptoms, akathisia, and sedation

Maintenance Monitoring

• Month 3: Repeat all baseline parameters 10
• Annually thereafter: Full metabolic panel, weight, blood pressure 10
• Ongoing: Monitor for extrapyramidal symptoms, weight gain, and metabolic changes

Key Safety Considerations

Extrapyramidal Symptoms

• Incidence: 8-13% at therapeutic doses (lower than haloperidol at 34%) 3
• Dose-related: Higher at 10 mg twice daily versus 5 mg twice daily 1
• Manage with dose reduction, switching to quetiapine/olanzapine, or adding propranolol 10-30 mg 2-3 times daily 10

Metabolic Effects

Asenapine has a more favorable metabolic profile than olanzapine 2, 12:

• Weight gain: Modest (mean 0.4 kg in elderly patients) 5
• Less than 5% of patients had clinically significant weight change in acute trials 3
• Lower risk of diabetes and dyslipidemia compared to olanzapine and clozapine 12

Unique Adverse Effects

• Oral hypoesthesia/dysgeusia: Occurs in ~5% of patients 2, 8, 9
• Typically transient and resolves with continued use
• Somnolence: 14% at 7.6 mg/24 hours transdermal 1

Hepatic Monitoring

• Transient ALT elevations more common with asenapine 1
• 1.6-3.1% of patients develop ALT ≥3× upper limit of normal 1
• Monitor liver enzymes at baseline, month 3, and if clinically indicated

Common Pitfalls to Avoid

1. Swallowing the sublingual tablet: Results in therapeutic failure due to extensive first-pass metabolism 1, 2, 9
2. Inadequate food/drink restriction: Reduces bioavailability; enforce 10-minute restriction 1, 8
3. Once-daily dosing: Ineffective due to pharmacokinetics; twice-daily dosing is required 1
4. Rapid titration in elderly: Increases risk of orthostatic hypotension and falls; use slower escalation 5
5. Ignoring baseline metabolic assessment: Essential for monitoring treatment-emergent metabolic changes 10, 11